Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

🤖 Plain-English Summary

BACKGROUND: , locking it in its inactive state. CONCLUSIONS: -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals.

🔑 Key Findings

• Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study.
• METHODS: -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy.
• The primary end point was objective response assessed by blinded independent central review.

🔗 Related Resources